Floatz logo

TACROLIMUS

T-Cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

83 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
GC Cell Corporation
Phase 2BBB
Brentuximab Vedotin
Yale University
Phase 4BBB
Rituximab
Memorial Sloan Kettering Cancer Center
Phase 2BB
Cyclophosphamide
GC Cell Corporation
Phase 3BB
LENALIDOMIDE
Samsung Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →